Tsai YC, Tai WC*, Liang CM, Wu CK, Tsai MC, Hu WH, Huang PY, Chen CH, Kuo YH, Yao CC*, Chuah SK. Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease. J Microbiol Immunol Infect. 2024 Oct 1:S1684-1182(24)00184-1. doi: 10.1016/j.jmii.2024.09.006. (SCI)
Tai WC, Wu IT, Wang HM, Huang PY, Yao CC, Wu CK, Yang SC, Liang CM*, Hsu PI, Chuah SK. The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan. J Microbiol Immunol Infect. 2024 Aug;57(4):601-608. (SCI)
Lin WC, Tai WC(Co-first), Chang CH, Tu CH, Feng IC, Shieh MJ, Chung CS, Yen HH, Chou JW, Wong JM, Liu YH, Huang TY, Chuang CH, Tsai TJ, Chiang FF, Lu CY, Hsu WH, Yu FJ, Chao TH, Wu DC, Ho AS, Lin HH, CFeng CL, Wu KL, Wong MW, Tung CC, Lin CC, Chen CC, Hu HM, Lu LS, Wei SC*. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study. Inflamm Bowel Dis. 2023 Nov 2;29(11):1730-1740. (SCI)
Tai WC, Yang SC, Yao CC, Wu CK , Liu AC, Lee CH, Kuo YH, Chuah SK*, Liang CM*. The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naive Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial. Infect Dis Ther. 2023 May;12(5):1415-1427. (SCI)
Lee YC, Tai WC*, Wu KL, Yao CC, Chuah SK. Per oral endoscopic myotomy for achalasia: A Taiwanese single-center experience. Adv Dig Med. 2022 Dec;9:241–246.
Ko CY, Yao CC, Li YC, Lu LS, Chou YP, Hu ML, Chiu YC, Chuah SK, Tai WC*. Clinical outcomes of endoscopic submucosal dissection for colorectal neoplasms: A single-center experience in Southern Taiwan.PLoS One. 2022 Oct 7;17(10):e0275723. (SCI)
Huang TH, Yang SC*, Tai WC*, Liang CM, Kuo CM, Yao CC, Wu CK, Kuo YH, Chou YP, Lee CH, Wu KL, Chuah SK. The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance. Biomed J. 2021 Dec;44(6S2):S275-S281. (SCI)
Tai WC, Wu KL*, Chuah SK*. An update on endoscopic treatment for achalasia: From peroral endoscopic myotomy to endolumenal functional lumen imaging probe. Adv Dig Med. 2021 Mar;8:8–9.(台灣消化醫學雜誌)
Tai WC, Liang CM, Bi KW, Kuo CM*, Lu LS, Wu CK, Yang SC, Kuo YH, Lee CH, Huang CF, Hsu CN, Hsu PI, Wu DC, Hu TH, Wu KL, Chuah SK*. A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial. Infect Drug Resist. 2019 Sep 16;12:2923-2931. (SCI)
Tai WC, Liang CM, Kuo CM, Huang PY, Wu CK, Yang SC, Kuo YH, Lin MT, Lee CH, Hsu CN, Wu KL, Hu TH, Chuah SK*. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019 Jun 1;74(6):1718-1724. (SCI)
Chuah SK, Lim CS, Liang CM, Lu HI,Wu KL,Changchien CS, Tai WC*. Bridging the Gap between Advancements in the Evolution of Diagnosis and Treatment towards Better Outcomes in Achalasia. BioMed Research International. 2019 Feb 6; 2019: 8549187. (SCI) Review
Wang HM, Liang CM, Wu CK, Chiu YC, Chou YP, Wu KL, Huang CC, Chuah SK, Tai WC*, Lu LS. Metachronous duodenal neuroendocrine tumors treated by endoscopic submucosal dissection. Advances in Digestive Medicine. 2017 June 2; 4(2):71-75. 台灣消化醫學雜誌
Wu CK, Liang CM, Hsu CN, Hung TH, Yuan LT, Nguang SH, Wang JW, Tseng KL, Ku MK8, Yang SC, Tai WC*, Shih CW, Hsu PI, Wu DC, Chuah SK. The Role of Adjuvant Acid Suppression on the Outcomes of Bleeding Esophageal Varices after Endoscopic Variceal Ligation. PLoS One. 2017 Jan 24;12(1):e0169884. (SCI)
Tsai CE, Liang CM, Lee CH, Kuo YH, Wu KL, Chiu YC, Tai WC*, Chuah SK. First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. Kaohsiung J Med Sci. 2016 Aug;32(8):397-402. (SCI)
Chuah SK(co-first), Liang CM(co-first), Lee CH, Chiou SS, Chiu YC, Hu ML, Wu KL, Lu LS, Chou YP, Chang KC, Kuo CH, Kuo CM, Hu TH, Tai WC*. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication. Medicine (Baltimore). 2016 May;95(19):e3586. (SCI)
Wu IT, Chuah SK, Lee CH, Liang CM, Lu LS, Kuo YH, Yen YH, Hu ML, Chou YP, Yang SC, Kuo CM, Kuo CH, Chiou SS, Chien CC, Chiang YS, Chiou SS, Hu TH, Tai WC*. Five-year sequential changes in secondary antibiotic resistances of Helicobacter pylori in Taiwan. World J Gastroenterol. 2015 Oct 7; 21(37): 10669-10674. (SCI)
Kuo MT, Yang SC(co-first), Lu LS(co-first), Hsu CN, Kuo YH, Kuo CH, Liang CM, Kuo CM, Wu CK, Tai WC*, Chuah SK. Predicting risk factors for rebleeding, infections, mortality following peptic ulcer bleeding in patients with cirrhosis and the impact of antibiotics prophylaxis at different clinical stages of the disease. BMC Gastroenterol. 2015 May 20;15:61. (SCI)
Yao CC, Wu IT (co-first), Lu LS, Lin SC, Liang CM, Kuo YH, Yang SC, Wu CK, Wang HM, Kuo CH, Chiou SS, Wu KL, Chiu YC, Chuah SK, Tai WC*. Endoscopic Management of Foreign Bodies in the Upper Gastrointestinal Tract of Adults. Biomed Res Int. 2015 July; 2015:658602. (SCI)
Tai WC, Liang CM(co-first), Lee CH, Chiu CH, Hu ML, Lu LS, Kuo YH, Kuo CM, Yen YH, Kuo CH, Chiou SS, Wu KL, Chiu YC, Hu TH, Chuah SK*. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A” Success Rate for First-Line Helicobacter pylori Eradication. Biomed Res Int. 2015 Jan;2015:623732. (SCI)
Liang CM, Cheng JW(co-first), Kuo CM, Chang KC, Wu KL, Tai WC*, Chiu KW, Chiou SS, Lin MT, Hu TH, Chuah SK. Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice. Biomed J. 2014 Sep-Oct.37(5):326-330. 長庚醫誌
Chuah SK, Tai WC(co-first), Lee CH*, Liang CM, Hu TH. Quinolone-Containing Therapies in the Eradication of Helicobacter pylori. BioMed Research International. 2014 Aug.; 2014 (2014): 151543. Review (SCI)
Tai WC, Lee CH, Chiou SS, Kuo CM, Kuo CH, Liang CM, Lu LS, Chiu CH, Wu KL, Chiu YC, Hu TH, Chuah SK*. The Clinical and Bacteriological Factors for Optimal Levofloxacin-Containing Triple Therapy in Second-Line Helicobacter pylori Eradication. PLoS One. 2014 Aug 20;9(8):e105822. (SCI)
Wu TC, Chuah SK, Chang KC, Wu CK, Kuo CH, Wu KL, Chiu YC, Hu TH, Tai WC*. Outcome of holiday and nonholiday admission patients with acute peptic ulcer bleeding: a real-world report from southern taiwan. Biomed Res Int. 2014 July;2014:906531. (SCI)
Tai WC, Chiu CH(co-first), Liang CM, Chang KC, Kuo CM, Chiu YC, Wu KL, Hu ML, Chou YP, Chiou SS, Chiu KW, Kuo CH, Hu TH, Lin MT, Chuah SK*. Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan. Gastroenterol Res Pract. 2013 Oct.; 2013:932478. (SCI)
Kao SS, Chen WC, Hsu PI, Chuah SK, Lu CL, Lai KH, Tsai FW, Chang CC, Tai WC*. The Frequencies of Gastroesophageal and Extragastroesophageal Symptoms in Patients with Mild Erosive Esophagitis, Severe Erosive Esophagitis, and Barrett's Esophagus in Taiwan. Gastroenterol Res Pract. 2013;2013:480325. (SCI)
Lu LS, Lin SC, Kuo CM, Tai WC*, Tseng PL, Chang KC, Kuo CH, Chuah SK. A real world report on intravenous high-dose and non-high-dose proton-pump inhibitors therapy in patients with endoscopically treated high-risk peptic ulcer bleeding. Gastroenterol Res Pract. 2012 July; 2012:858612. (SCI)
Tai WC, Hu TH, Lee CH, Chen HH, Huang CC, Chuah SK*. A no-perianal tuberculosis: 15 years of clinical experiences in Southern Taiwan. Colorectal Dis. 2010 Jul;12(7 Online):e114-20. (SCI)
Tai WC, Changchien CS, Hu TH, Huang CC, Chuah SK*, Lee CM. Pancreatic head cancer with distant duodenal metastasis: a case report with rare endoscopic presentations. Am J Med Sci. 2009 Jul;338(1):75-7. (SCI)
Tai WC, Hu TH, Wang JH, Hung CH, Lu SN, Changchien CS, Lee CM*. Clinical implications of alpha-fetoprotein in chronic hepatitis C. J Formos Med Assoc. 2009 Mar;108(3):210-8. (SCI)
Tai WC, Chuah SK, Lin JW, Chen HH, Huang HY, Kuo CM, Yi LN, Lee CM, Changchien CS, Hu TH*. Colorectal mesenchymal tumors - from smooth muscle tumors to stromal tumors. Oncol Rep. 2008 Nov;20(5):1157-64. (SCI)
Liang CM, Wu KL, Chou YP, Tai WC*, Chiu YC, Changchien CS, Chiou SS, Hu TH, Chuah SK. PREVALENCE AND ASSOCIATED FACTORS OF HYPERECHOIC PANCREAS ON SONOGRAPHY. Gastroenterol J Taiwan 2011; 28(3): 281-288.
Tai WC, Kuo CM, Lee CH, Chuah SK*, Huang CC, Hu TH, Wang JH, Chang KC, Tseng PL, Changchien CS, Lee CM. Liver Tuberculosis in Southern Taiwan: 15-years Clinical Experience. J Int Med Taiwan. 2008 Oct;19(5):410-7.
